Patient preference favoring treatment discontinuation was improved during treatment with Entyvio or Stelara compared with anti-TNF therapy in patients with inflammatory bowel disease, according to study results.
Dana J. Lukin, MD, PhD, of the division of the Jill Roberts Center for IBD at Weill Cornell Medical College, and colleagues wrote that non-adherence to medication presents a critical risk in IBD. However, the reasons why patients prefer biologic discontinuation are not well understood.
“Few studies have retrospectively examined potential risk factors of non-adherence in patients
Full Article: https://www.healio.com/news/gastroenterology/20200930/patientfavored-discontinuation-improved-with-entyvio-stelara-in-ibd